BMSN .0032 POISED TO BUST INTO THE $TRILLION PHARMA SCENE

New Post Public Reply Private Reply Replies (0) Message Board
patientgal
BMSN .0032 POISED TO BUST INTO THE $TRILLION PHARMA SCENE ANY DAY NOW!

Regen Biopharma, Subsidiary of Bio-Matrix Scientific Group is that much closer to the US FDA's Orphan Drug approval to begin clinical trials for their Trademark autologous ( patient derives) stem cell treatment HemaXellerate for Aplastic Anemia. 

HemaXellerate is just one of several proposed treatments from the patented  HemXellerate approach to combating life threatening diseases. 

And if teaching a patient's body to attack deadly intruders by way of their own stem cells is not out-of-this-world, try this on for size: 

siRNA GENE SILENCING: In a nutshell, Dr. Wei-Ping Min, long-time friend of & mentor to Dr. Thomas Ichim, CSO of Regen Biopharma, has developed a process whereby the genetic components contributing to the  growth of cancer are silenced. 

But, they are not stopping there--the latest licensing deal with Benitec Australia coupled with Dr. Min's siRNA science not only will tell cancer to shut up and get the bleep out, but will also help to give a mega boost to the patients  immune system . 

Oh, and the patented treatments have world-wide protection.

CAN YOU SAY CHA-CHING?

BIG PHARMA AND THEIR DEEP POCKETS ARE WATCHING!

Bio-Matrix Scientific Group: 

-----Fully  Reporting
-----Totally Transparent 
-----Comprised of world renowned scientists considered leaders in the world of stem cell medicine & gene silencing 
-----Aggressively pursuing their position in a trillion dollar pharmaceutical market while at the same time working just as hard to improve quality of life! 
----- NO DUMPING OF SHARES BY THE COMPANY  CEO REGARDLESS OF WHAT SOME WILL HAVE YOU THINK!

BMSN--a steal @ 0032. A price that is soon to be but a very distant memory!


SAN DIEGO, CA--(Marketwired - Aug 16, 2013) - Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update today on the cancer immunotherapy program currently under development by Regen BioPharma Inc., a wholly owned subsidiary of BMSN. 

"The operating  objective of Regen BioPharma is to identify, develop, and commercialize intellectual property which has demonstrated preclinical efficacy, and addresses significant markets," said David Koos, CEO of Regen BioPharma. 


Quote:

"On May 6, 2013, we acquired issued patent # 8,389,708 from Dr. Wei-Ping Min of the University of Western Ontario, as well as proprietary know-how covering means of inducing immune mediated killing of melanoma and breast cancer. This data has been published in two peer-reviewed scientific publications (1, 2). Last week, we licensed from Benitec Australia Ltd rights to patented biological mechanisms that control the gene manipulation processes. These processes dovetail into the Wei-Ping Min technology to induce regression of cancer. We believe that the combination of these patents provide us international patent coverage for development of this technology into clinical trials and eventually as a non-toxic alternative to current day  chemotherapy and radiotherapy."




Current day cancer immunotherapy is based on stimulating immune responses to cancer cells. Unfortunately, in the majority of patients, the tumor reduces ability of the immune response to kill the tumor resulting in reduced efficiency of many prior cancer vaccines. 

By blocking the mechanisms by which the tumor escapes from the immune response, several companies have developed successful cancer drugs, for example, Bristol-Myers Squibb, which developed Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab blocks the immune inhibitory molecule CTLA-4, which results in augmentation of immune responses. 

" Regen's approach, which is currently in late-stage preclinical testing, involves blocking the immune suppressive gene IDO, while concurrently using dendritic cells to stimulate the immune system," said Dr. Thomas Ichim, Chief Scientific Officer for Regen BioPharma. "Through the combination approach, and based on the published data, we are hoping to offer a new weapon in the fight against breast cancer ." 

Regen BioPharma is currently conducting toxicology experiments on its therapeutic approach, with anticipated FDA filing in the 4th Quarter of 2013.

References 
1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77. 
2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46. 
3. www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018 

About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative  medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website 
Scroll down for more posts ▼

Top 10 Most Recent News Articles

3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 274

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 214

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Hoymiles Shines at RE+ with Innovative Solar Solutions

Updated Category News Views 246

Hoymiles Unveils Exciting Innovations at RE+ The 2024 edition of RE+ was a major event where Hoymiles showcased its groundbreaking developments in power electronics, particularly focusing on photovoltaic (PV) systems and energy storage technologies. As a leader in this sector, the company drew in audiences with its cutting-edge microinverter solutions, crafted to address...

Continue Reading
Ageas Enhances Shareholder Value with Buy-Back Progress

Updated Category News Views 161

Ageas Advances Share Buy-Back Program Ageas has announced updates regarding its share buy-back program initiated on August 28, 2024. As part of this initiative, the company has successfully repurchased 38,549 of its shares between December 30, 2024, and January 3, 2025. This strategic move is part of Ageas's ongoing efforts to enhance shareholder value through the...

Continue Reading
Empowering Investigators: Genetec's Innovative Vehicle Data Tools

Updated Category News Views 220

Unlocking New Possibilities for Law Enforcement In a significant advancement for law enforcement capabilities, a leading technology provider announced innovative features designed to streamline the collection and sharing of vehicle data for investigations. The integration of these tools aims to enhance the speed and security of evidence handling, assisting detectives in...

Continue Reading
Cathay Cargo and Descartes Ensure Safe Panda Transport

Updated Category News Views 229

Enhancing Logistics: The Role of Technology in Cargo Transport In a remarkable effort to safeguard one of nature's most beloved creatures, Cathay Cargo, a prominent air freight service provider, collaborated with Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG). Utilizing Descartes’ innovative Bluetooth Low Energy tracking solution, they successfully monitored the safe...

Continue Reading
NB Private Equity Partners Enhances Shareholder Value Through Buyback

Updated Category News Views 150

Introduction to Recent Share Buyback Activity NB Private Equity Partners, often referred to as NBPE, has recently initiated a significant share buyback of its Class A Shares. This buyback aligns with the authority provided by shareholders and underscores the company’s commitment to enhancing shareholder value. Details of the Share Buyback The transaction has been made...

Continue Reading